Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|February 28, 1996

HDI 3000 drives ATL revenue numbers

Ultrasound vendor ATL continues to enjoy strong momentum fromsales of its premium HDI 3000 scanner. The Bothell, WA, companythis month reported year-end financial results that show worldwiderevenues up 9%. For 1995, ATL had revenues of $399.4 million

Ultrasound vendor ATL continues to enjoy strong momentum fromsales of its premium HDI 3000 scanner. The Bothell, WA, companythis month reported year-end financial results that show worldwiderevenues up 9%.

For 1995, ATL had revenues of $399.4 million compared withsales of $366.2 million in 1994. Net income improved sharply,to a net profit of $12 million in 1995 from a net loss of $20.2million in 1994, when ATL took charges relating to its consolidationof Interspec and litigation with SRI International. In 1995, ATLalso enjoyed a one-time benefit of $6.5 million related to a favorablestate sales tax audit and its new joint venture with Hitachi (SCAN11/22/95).

ATL's fourth-quarter numbers show that its momentum increasedas the year drew to a close. Fourth-quarter revenues rose 14%to $119.1 million, compared with $104.7 million in the same periodof 1994. Net income was $12.2 million compared with a net lossof $5.8 million in the fourth quarter of 1994. The Hitachi investmentof $6.2 million was recorded in the fourth quarter of 1995.

The company's growth was due to market acceptance of HDI 3000,as well as strong sales of ATL's mid-range Apogee product linein international markets, according to chairman and CEO DennisFill. ATL this month announced that as of the end of 1995 it hadshipped over 1000 HDI 3000 scanners. The company also said thatit was named as a preferred vendor for radiology ultrasound byUniversity HealthSystem Consortium of Oak Brook, IL.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.